Eltrombopag Catalog No.:M10203-2 Synthetic lethal RNAi screening identifies

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

Viral strains that are resistant to zidovudine (AZT) or lamivudine (3TC) are generally

were compared to those of linezolid in 67 susceptible and drug-resistant clinical isolates of Mycobacterium tuberculosis

SJ000291942 induces p-SMAD1/5/8 maximally at 1hr of treatment

5-dimethyl-4-[(2S)-N

Eltrombopag Catalog No.:M10203-2 Synthetic lethal RNAi screening identifiesEltrombopag is a small molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production. Eltrombopag was